It was a genuine question, as the NICE costing is essential to any projected short term revenue.
And if NWBO doesn't get that MAA soon, it's game over.
Given that Chemo/ radio cost per patient is <£2,000 per patient to the NHS, so given the 'meaningful' claimed 13% OS advantage.
I say that the per patient 'vaccine' cost has to be < £3,000, as each patient will still receive SOC.
And as Advent will take the earnings, NWBO will still be prerevenue .
So your ONLY hope of getting a good return on investment , will be a buyout.
There simply is no fortune to be had with the NHS.
Market Data 
Markets 
AI
